North Star Asset Management Inc. Buys Shares of 40,676 Novo Nordisk A/S $NVO

Posted by Brenda Bartman on Aug 28th, 2026

North Star Asset Management Inc. bought a new position in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 40,676 shares of the company’s stock, valued at approximately $1,950,000.

A number of other large investors have also recently made changes to their positions in NVO. Revolve Wealth Partners LLC boosted its stake in Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after purchasing an additional 200 shares during the period. AQR Capital Management LLC increased its position in shares of Novo Nordisk A/S by 21.0% during the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock valued at $4,312,000 after buying an additional 10,758 shares during the period. Sivia Capital Partners LLC lifted its holdings in shares of Novo Nordisk A/S by 18.2% in the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after buying an additional 1,587 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Novo Nordisk A/S by 26.3% in the second quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock worth $28,967,000 after buying an additional 87,467 shares in the last quarter. Finally, Gamco Investors INC. ET AL bought a new position in shares of Novo Nordisk A/S in the second quarter valued at approximately $314,000. 11.54% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

NVO has been the subject of several recent analyst reports. Berenberg Bank set a $47.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, August 12th. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Wall Street Zen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Finally, Weiss Ratings upgraded Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. Four equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $64.94.

View Our Latest Analysis on Novo Nordisk A/S

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

Positive Sentiment: China’s National Medical Products Administration accepted Novo Nordisk’s application for an oral version of Wegovy. The filing is not an approval, but authorization could expand access to Novo’s obesity treatment and strengthen its position against Eli Lilly in China. China drug regulator accepts Novo Nordisk’s application for oral Wegovy
Neutral Sentiment: Novo’s shares recently moved above their 200-day moving average, a potentially constructive technical signal. However, the stock remains well below its prior peak, and the longer-term trend is still being shaped primarily by earnings and competitive developments. Novo Nordisk stock price passes above 200 day moving average
Negative Sentiment: Deutsche Bank downgraded NVO to Sell from Hold and reduced its price target to 265 Danish kroner from 290 kroner. The bank cited doubts about Novo’s ability to resume growth following mixed second-quarter results, increasing competition and concerns about an impending patent-related revenue cliff, particularly around 2027. Novo Nordisk stock falls as Deutsche Bank downgrades shares to sell
Negative Sentiment: Analysts also questioned Novo’s development pipeline after Ziltivekimab was described as effectively out of the picture following a failed late-stage cardiovascular trial. This removes a potential future growth driver as investors look for products that can offset slowing momentum in Ozempic and Wegovy. Novo’s 2027 growth rebound faces fresh doubts
Negative Sentiment: Investors continue to monitor intensifying competition from Eli Lilly and lower-cost or counterfeit versions of Novo’s blockbuster GLP-1 medicines. These pressures could affect pricing, market share and the pace of revenue growth. Novo Nordisk shares drop as bank downgrade reflects growth concerns

Novo Nordisk A/S Trading Down 2.0%

NYSE NVO opened at $46.27 on Friday. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The stock’s 50-day simple moving average is $47.98 and its two-hundred day simple moving average is $43.88. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $64.16. The company has a market capitalization of $206.58 billion, a price-to-earnings ratio of 11.31, a PEG ratio of 4.25 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. The firm had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%. Research analysts forecast that Novo Nordisk A/S will post 3.43 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a dividend, which was paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th were paid a $0.5786 dividend. The ex-dividend date of this dividend was Monday, August 17th. This represents a yield of 258.0%. Novo Nordisk A/S’s dividend payout ratio is currently 20.05%.

Novo Nordisk A/S Company Profile

(Free Report)

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.